Neumora files 8-K on NMRA-898 Phase 1 SAD/MAD initiation

Rhea-AI Filing Summary

Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.

This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001885522false00018855222025-10-272025-10-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2025

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41802	84-4367680
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
260 Arsenal Place, Suite 1
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 760-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NMRA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 27, 2025, Neumora Therapeutics, Inc. (the “Company”) issued a press release announcing the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release dated October 27, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUMORA THERAPEUTICS, INC.
Date:	October 27, 2025	By:	/s/ Michael Milligan
			Michael Milligan Chief Financial Officer

FAQ

What did Neumora Therapeutics (NMRA) announce in its 8-K?

The company initiated a Phase 1 SAD/MAD clinical study of NMRA-898 and furnished the press release as Exhibit 99.1.

What stage of development is NMRA-898 now in?

NMRA-898 has entered a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study.

When was the NMRA-898 Phase 1 initiation disclosed?

It was disclosed on October 27, 2025.

Where can I find more details about the announcement?

Additional detail is provided in the press release attached as Exhibit 99.1.

Does this 8-K include financial results or guidance for NMRA?

No. The filing reports an operational update regarding a Phase 1 study and does not present financial data.

What exchange does NMRA trade on?

Neumora Therapeutics’ common stock trades on The Nasdaq Global Select Market under the ticker NMRA.